AVTE News and Press, Aerovate Therapeutics Inc. From 11/13/23

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the qua...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Aerovate Therapeutics Inc. (AVTE) is expected to report $-0.7 for Q3 2023

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-08-14 09:16:37 ET Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q2 GAAP EPS of -$0.76. Cash, cash equivalents and available-for sale securities totaled $150.1 million as of June 30, 2023, compared to $129.2 million as of December 31, 2022. For further de...

WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the qua...

WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as...

2023-06-28 08:00:00 ET Summary Aerovate Therapeutics is testing an inhaled imatinib formulation in PAH patients. Novartis tested imatinib in PAH and found it effective but with a poor safety profile. AVTE hopes that an inhaled version will be safer. Aerovate Therapeu...

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing Formulation impacted lung exposure with dry powder demonstrating greater lung exposure than suspension or solution and greater lung exposure vs oral or IV...

2023-05-16 04:18:57 ET Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q1 GAAP EPS of -$0.67 misses by $0.07 . Cash, cash equivalents and short-term investments totaled $118.9 million as of March 31, 2023, compared to $129.2 million as of December 31, 2022. W...